While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication. A groundbreaking ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and ...

Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of ...

Explore how MRI imaging acts as a pivotal scientific hub, bridging the gap between preclinical and clinical research to drive ...

The dire circumstances facing cystic fibrosis patients in Cuba have come to light through a heartfelt letter sent to our news ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.